Orchestra BioMed Holdings (OBIO) Times Interest Earned (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Times Interest Earned of -$8.24 for Q1 2026, up 79.88% year-over-year from -$4.58 in Q1 2025, and down 144.04% quarter-over-quarter from $18.71 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Times Interest Earned (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Times Interest Earned for 6 consecutive years, with -$8.24 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 79.88% year-over-year to -$8.24; the TTM figure through Mar 2026 stood at -$20.52 (up 93.02% YoY), while the FY2025 annual figure was -$0.48, up 30.12% from the prior year.
- Times Interest Earned fell to -$8.24 in Q1 2026 per OBIO's latest filing, from $18.71 in the prior quarter.
- Across five years, Times Interest Earned topped out at $28.8 in Q4 2024 and bottomed at -$90.28 in Q3 2025.
- Historically, Times Interest Earned has averaged -$17.45 across 5 years, with a median of -$11.63 in 2024.
- Annual changes were most pronounced in 2022 — Times Interest Earned slumped 1132.01% — and 2023, when it soared 92.55%.
- Orchestra BioMed Holdings' Times Interest Earned stood at -$37.8 in 2022, then soared by 94.87% to -$1.94 in 2023, then soared by 1586.36% to $28.8 in 2024, then sank by 35.04% to $18.71 in 2025, then slumped by 144.04% to -$8.24 in 2026.
- Business Quant data shows OBIO's Times Interest Earned at -$8.24 in Q1 2026, $18.71 in Q4 2025, and -$90.28 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -7.61 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.61 |
| Mar 31, 2026 | -8.24 |
| Dec 31, 2025 | 18.71 |
| Sep 30, 2025 | -90.28 |
| Jun 30, 2025 | -8.62 |
| Mar 31, 2025 | -40.95 |
| Dec 31, 2024 | 28.80 |
| Sep 30, 2024 | -12.77 |
| Jun 30, 2024 | -2.02 |
| Mar 31, 2024 | -10.49 |
| Sep 30, 2023 | -1.94 |
| Jun 30, 2023 | -3.24 |
| Mar 31, 2023 | -32.89 |
| Dec 31, 2022 | -37.80 |
| Sep 30, 2022 | -26.01 |
| Jun 30, 2022 | -29.70 |
| Mar 31, 2022 | -21.73 |
| Dec 31, 2021 | -3.07 |
| Sep 30, 2021 | -3.15 |
| Jun 30, 2021 | -3.21 |